<p>阿默普萊斯金融公司在最近向證券交易委員會（SEC）提交的 13F 文件中表示，在第四季度將其在西氏醫藥服務公司（NYSE:WST - 免費報告）的持股增加了 21.0%。該基金在本季度購買了額外的 29,118 股後，持有 167,746 股該醫療器械供應商的股票。截至最近報告期末，阿默普萊斯金融公司持有的西氏醫藥服務公司約佔 0.23%，價值 54,947,000 美元。</p>
<ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
<p>其他幾家對沖基金也增加或減少了在 WST 的持股。Quadrant Capital Group LLC 在第四季度將其在西氏醫藥服務公司的股份增加了 5.4%。Quadrant Capital Group LLC 現在擁有 626 股該醫療器械供應商的股票，價值 205,000 美元，此前在上個季度購買了額外的 32 股。Baron Wealth Management LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 1.9%。Baron Wealth Management LLC 現在擁有 1,926 股該醫療器械供應商的股票，價值 631,000 美元，此前在該期間購買了額外的 35 股。Exchange Traded Concepts LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 18.9%。Exchange Traded Concepts LLC 現在擁有 239 股該醫療器械供應商的股票，價值 78,000 美元，此前在上個季度購買了額外的 38 股。Lake Street Advisors Group LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 5.8%。Lake Street Advisors Group LLC 現在擁有 711 股該醫療器械供應商的股票，價值 233,000 美元，此前在該期間購買了額外的 39 股。最後，Cornerstone Planning Group LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 57.1%。Cornerstone Planning Group LLC 現在擁有 110 股該醫療器械供應商的股票，價值 38,000 美元，此前在上個季度購買了額外的 40 股。目前 93.90% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師觀點</h2>
<p>WST 已成為多份研究報告的主題。StockNews.com 在 2 月 27 日的報告中將西氏醫藥服務的股票評級從 “買入” 下調至 “持有”。Stephens 在 4 月 21 日的研究報告中將西氏醫藥服務的評級上調至 “強力買入”。Evercore ISI 在 3 月 18 日的研究報告中開始覆蓋西氏醫藥服務。他們對該股票給予了 “跑贏大盤” 的評級，並設定了 275.00 美元的目標價。德意志銀行將西氏醫藥服務的股票評級從 “持有” 上調至 “買入”，並在 2 月 14 日的研究報告中為該公司設定了 250.00 美元的目標價。最後，KeyCorp 在 2 月 14 日的研究報告中將西氏醫藥服務的股票目標價從 470.00 美元下調至 325.00 美元，並對該股票給予了 “增持” 評級。兩位投資分析師對該股票給予了持有評級，六位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat 的數據，西氏醫藥服務的平均評級為 “適度買入”，共識目標價為 332.50 美元。</p>
<ul>
<li>今年將推動標準普爾 500 表現的因素是什麼？</li>
</ul>
<p><strong>獲取我們對西氏醫藥服務的最新分析</strong></p>
<h2>西氏醫藥服務股票下跌 0.6%</h2>
<p>西氏醫藥服務（NYSE:WST）週五開盤價為 213.39 美元。該公司的 50 日移動平均價格為 216.55 美元，200 日移動平均價格為 278.35 美元。公司市值為 153.3 億美元，市盈率為 31.90，PEG 比率為 6.74，貝塔值為 1.14。公司的債務與股本比率為 0.08，流動比率為 2.79，速動比率為 2.23。西氏醫藥服務公司的一年低點為 187.43 美元，一年高點為 367.71 美元。</p>
<ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
<p>西氏醫藥服務（NYSE:WST - 獲取免費報告）最近在 4 月 24 日發佈了其財報。該醫療器械供應商報告本季度每股收益為 1.45 美元，超出市場共識預期的 1.22 美元，超出 0.23 美元。西氏醫藥服務的股本回報率為 18.60%，淨利潤率為 17.03%。該公司在本季度的收入為 6.98 億美元，而分析師預期為 6.8524 億美元。在去年同期，該公司的每股收益為 1.56 美元。該公司的收入同比增長 0.4%。分析師預計西氏醫藥服務公司本財年的每股收益將達到 6.62 美元。</p>
<h2>西氏醫藥服務股息公告</h2>
<p>該公司最近還披露了一項季度股息，將於 8 月 6 日（星期三）支付。7 月 30 日（星期三）登記的股東將獲得每股 0.21 美元的股息。這相當於年化股息為 0.84 美元，股息收益率為 0.39%。該股息的除息日期為 7 月 30 日（星期三）。西氏醫藥服務的股息支付比率目前為 13.19%。</p>
<h2>西氏醫藥服務簡介</h2>
<p>（免費報告）</p>
<p>西氏醫藥服務公司設計、製造和銷售用於注射藥物和醫療產品的封閉和輸送系統，業務覆蓋美洲、歐洲、中東、非洲和亞太地區。它分為兩個部門，專有產品和合同製造產品。</p>
<h2>特色故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是西氏醫藥服務</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>GlobalFoundries 股票觸底：反彈即將來臨嗎？</li>
<li>澳大利亞證券交易所（ASX）是什麼</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>3 只小盤股具有巨大的回報潛力</li>
<li>分析師最愛的比特幣礦工 CleanSpark：值得 hype 嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
<p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而西氏醫藥服務並不在名單上。</p>
<p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西氏醫藥服務

阿默普萊斯金融

<p>Ameriprise Financial Inc. 在第四季度將其在西氏醫藥服務公司（NYSE:WST）的持股增加了 21.0%，增持了 29,118 股，總持股達到 167,746 股，價值約為 5490 萬美元。其他對沖基金也調整了在 WST 的持倉。分析師對該股票的評級意見不一，普遍評級為 “適度買入”，目標價為 332.50 美元。WST 股票開盤價為 213.39 美元，市值為 153.3 億美元，市盈率為 31.90。該公司報告每股收益為 1.45 美元，超出預期</p>

<p>Ameriprise Financial Inc. boosted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 21.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 167,746 shares of the medical instruments supplier's stock after buying an additional 29,118 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.23% of West Pharmaceutical Services worth $54,947,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>阿默普萊斯金融公司在最近向證券交易委員會（SEC）提交的 13F 文件中表示，在第四季度將其在西氏醫藥服務公司（NYSE:WST - 免費報告）的持股增加了 21.0%。該基金在本季度購買了額外的 29,118 股後，持有 167,746 股該醫療器械供應商的股票。截至最近報告期末，阿默普萊斯金融公司持有的西氏醫藥服務公司約佔 0.23%，價值 54,947,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
</div><p>Several other hedge funds have also added to or reduced their stakes in WST. Quadrant Capital Group LLC increased its position in shares of West Pharmaceutical Services by 5.4% during the 4th quarter. Quadrant Capital Group LLC now owns 626 shares of the medical instruments supplier's stock valued at $205,000 after purchasing an additional 32 shares during the last quarter. Baron Wealth Management LLC grew its position in West Pharmaceutical Services by 1.9% during the fourth quarter. Baron Wealth Management LLC now owns 1,926 shares of the medical instruments supplier's stock valued at $631,000 after buying an additional 35 shares during the period. Exchange Traded Concepts LLC increased its holdings in West Pharmaceutical Services by 18.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier's stock worth $78,000 after buying an additional 38 shares during the last quarter. Lake Street Advisors Group LLC raised its position in West Pharmaceutical Services by 5.8% in the fourth quarter. Lake Street Advisors Group LLC now owns 711 shares of the medical instruments supplier's stock worth $233,000 after acquiring an additional 39 shares during the period. Finally, Cornerstone Planning Group LLC boosted its stake in West Pharmaceutical Services by 57.1% in the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 40 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家對沖基金也增加或減少了在 WST 的持股。Quadrant Capital Group LLC 在第四季度將其在西氏醫藥服務公司的股份增加了 5.4%。Quadrant Capital Group LLC 現在擁有 626 股該醫療器械供應商的股票，價值 205,000 美元，此前在上個季度購買了額外的 32 股。Baron Wealth Management LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 1.9%。Baron Wealth Management LLC 現在擁有 1,926 股該醫療器械供應商的股票，價值 631,000 美元，此前在該期間購買了額外的 35 股。Exchange Traded Concepts LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 18.9%。Exchange Traded Concepts LLC 現在擁有 239 股該醫療器械供應商的股票，價值 78,000 美元，此前在上個季度購買了額外的 38 股。Lake Street Advisors Group LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 5.8%。Lake Street Advisors Group LLC 現在擁有 711 股該醫療器械供應商的股票，價值 233,000 美元，此前在該期間購買了額外的 39 股。最後，Cornerstone Planning Group LLC 在第四季度將其在西氏醫藥服務公司的持股增加了 57.1%。Cornerstone Planning Group LLC 現在擁有 110 股該醫療器械供應商的股票，價值 38,000 美元，此前在上個季度購買了額外的 40 股。目前 93.90% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>WST has been the topic of a number of research reports. StockNews.com cut shares of West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 27th. Stephens upgraded West Pharmaceutical Services to a &#34;strong-buy&#34; rating in a research note on Monday, April 21st. Evercore ISI began coverage on West Pharmaceutical Services in a research note on Tuesday, March 18th. They issued an &#34;outperform&#34; rating and a $275.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $250.00 target price for the company in a research report on Friday, February 14th. Finally, KeyCorp lowered their price target on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, West Pharmaceutical Services has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $332.50.</p>
<div class="lb-trans"><p>WST 已成為多份研究報告的主題。StockNews.com 在 2 月 27 日的報告中將西氏醫藥服務的股票評級從 “買入” 下調至 “持有”。Stephens 在 4 月 21 日的研究報告中將西氏醫藥服務的評級上調至 “強力買入”。Evercore ISI 在 3 月 18 日的研究報告中開始覆蓋西氏醫藥服務。他們對該股票給予了 “跑贏大盤” 的評級，並設定了 275.00 美元的目標價。德意志銀行將西氏醫藥服務的股票評級從 “持有” 上調至 “買入”，並在 2 月 14 日的研究報告中為該公司設定了 250.00 美元的目標價。最後，KeyCorp 在 2 月 14 日的研究報告中將西氏醫藥服務的股票目標價從 470.00 美元下調至 325.00 美元，並對該股票給予了 “增持” 評級。兩位投資分析師對該股票給予了持有評級，六位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat 的數據，西氏醫藥服務的平均評級為 “適度買入”，共識目標價為 332.50 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年將推動標準普爾 500 表現的因素是什麼？</li>
</ul>
</div><p><strong>Get Our Latest Analysis on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>獲取我們對西氏醫藥服務的最新分析</strong></p>
</div><h2>West Pharmaceutical Services Stock Down 0.6 %</h2>
<div class="lb-trans"><h2>西氏醫藥服務股票下跌 0.6%</h2>
</div><p>Shares of NYSE:WST opened at $213.39 on Friday. The firm has a fifty day moving average price of $216.55 and a two-hundred day moving average price of $278.35. The company has a market cap of $15.33 billion, a price-to-earnings ratio of 31.90, a PEG ratio of 6.74 and a beta of 1.14. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. West Pharmaceutical Services, Inc. has a one year low of $187.43 and a one year high of $367.71.</p>
<div class="lb-trans"><p>西氏醫藥服務（NYSE:WST）週五開盤價為 213.39 美元。該公司的 50 日移動平均價格為 216.55 美元，200 日移動平均價格為 278.35 美元。公司市值為 153.3 億美元，市盈率為 31.90，PEG 比率為 6.74，貝塔值為 1.14。公司的債務與股本比率為 0.08，流動比率為 2.79，速動比率為 2.23。西氏醫藥服務公司的一年低點為 187.43 美元，一年高點為 367.71 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, topping the consensus estimate of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business had revenue of $698.00 million during the quarter, compared to analysts' expectations of $685.24 million. During the same period in the previous year, the business earned $1.56 earnings per share. The firm's revenue was up .4% on a year-over-year basis. Analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>西氏醫藥服務（NYSE:WST - 獲取免費報告）最近在 4 月 24 日發佈了其財報。該醫療器械供應商報告本季度每股收益為 1.45 美元，超出市場共識預期的 1.22 美元，超出 0.23 美元。西氏醫藥服務的股本回報率為 18.60%，淨利潤率為 17.03%。該公司在本季度的收入為 6.98 億美元，而分析師預期為 6.8524 億美元。在去年同期，該公司的每股收益為 1.56 美元。該公司的收入同比增長 0.4%。分析師預計西氏醫藥服務公司本財年的每股收益將達到 6.62 美元。</p>
</div><h2>West Pharmaceutical Services Dividend Announcement</h2>
<div class="lb-trans"><h2>西氏醫藥服務股息公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio is currently 13.19%.</p>
<div class="lb-trans"><p>該公司最近還披露了一項季度股息，將於 8 月 6 日（星期三）支付。7 月 30 日（星期三）登記的股東將獲得每股 0.21 美元的股息。這相當於年化股息為 0.84 美元，股息收益率為 0.39%。該股息的除息日期為 7 月 30 日（星期三）。西氏醫藥服務的股息支付比率目前為 13.19%。</p>
</div><h2>West Pharmaceutical Services Profile</h2>
<div class="lb-trans"><h2>西氏醫藥服務簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>西氏醫藥服務公司設計、製造和銷售用於注射藥物和醫療產品的封閉和輸送系統，業務覆蓋美洲、歐洲、中東、非洲和亞太地區。它分為兩個部門，專有產品和合同製造產品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是西氏醫藥服務</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>GlobalFoundries 股票觸底：反彈即將來臨嗎？</li>
<li>澳大利亞證券交易所（ASX）是什麼</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>3 只小盤股具有巨大的回報潛力</li>
<li>分析師最愛的比特幣礦工 CleanSpark：值得 hype 嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而西氏醫藥服務並不在名單上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

阿默普萊斯金融公司購入了西氏醫藥服務公司（NYSE: WST）的 29,118 股股票